Premji Invest led a $150m Series D financing round in Enveda.

Premji Invest, a venture capital firm, led a $150m Series D financing round in Enveda, a drug discovery and development company, with participation from Baillie Gifford, Kinnevik, Lingotto Investment Management, Peakline Partners, FPV, Socium Ventures, Dimension, Level Ventures, Henry Kravis, IA Ventures, and Lux Capital. “Enveda is proving that it’s possible to generate novel and first-in-class small molecule therapeutics at an unprecedented speed, scale, and efficiency. We believe there is a large unexplored search space for novel medicines, and Enveda has built the platform to translate life’s chemistry into treatments that could be transformative for millions of patients across the globe. This team is turning breakthrough science into medicines at a pace that is exceptionally rare, and are on their way to building what could be an industry-defining company,” Akshay Rai, Premji Invest Principal, Healthtech and Biotech.